Conference Calendar - The 88th EAS Congress

Introduction

Introduction to the scientific programme

Session Type

Introduction

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

12:55 - 13:00

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

CME Session

Prevention strategies for CV health

Session Type

CME Session

Chair(s)

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

13:00 - 14:30

Session Ticket

Session Evaluation

Please enter to our survey here

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1584,"presentation":"Introduction","session":"Prevention strategies for CV health","presenter":"Alexandros D. Tselepis, Greece","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5287.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/Alexandros Tselepis - EAS20 - 1584 - Introduction.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/103\/Alexandros Tselepis - EAS20 - 1584 - Introduction.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/F4D52173.jpg","data":[],"tracks":[]}]},{"name":"1. Precision nutrition and CVD management","mode":"playlist","public":true,"info":{"id":1502,"presentation":"1. Precision nutrition and CVD management","session":"Prevention strategies for CV health","presenter":"Jogchum Plat, Netherlands","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/3150.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/Jogchum Plat - EAS20 - 1502 - Precision nutrition and CVD management.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/103\/Jogchum Plat - EAS20 - 1502 - Precision nutrition and CVD management.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/E431E40B.jpg","data":[],"tracks":[]}]},{"name":"2. Behaviour change in CVD prevention","mode":"playlist","public":true,"info":{"id":1503,"presentation":"2. Behaviour change in CVD prevention","session":"Prevention strategies for CV health","presenter":"Heike Englert, Germany","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5380.jpg"},"playlist":[{"name":"Heike Engert - ID1503 - EAS20","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/1503.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/103\/1503.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/573F0007.jpg","data":[],"tracks":[]}]},{"name":"3. Can technology improve adherence to lifestyle?","mode":"playlist","public":true,"info":{"id":1504,"presentation":"3. Can technology improve adherence to lifestyle?","session":"Prevention strategies for CV health","presenter":"Gil Blander PhD, United States of America","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5388.jpg"},"playlist":[{"name":"103_1504_4_edit","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/103_1504_4_edit.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/103\/103_1504_4_edit.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/91667BC3.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/103_1504_4_edit.vtt"}]},{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1535,"presentation":"Panel Discussion with Live Q&A","session":"Prevention strategies for CV health","presenter":"\u017deljko Reiner, Croatia, Alexandros D. Tselepis, Greece, Jogchum Plat, Netherlands, Heike Englert, Germany, Gil Blander PhD, United States of America","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5287.jpg"},"playlist":[{"name":"Q&A","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/Q&A-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/103\/Q&A-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/103\/668BDA91.jpg","data":[],"tracks":[]}]}]

Joint symposium

NLA/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines

Session Type

Joint symposium

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

14:30 - 15:30

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Targets and goals - The EAS way","mode":"playlist","public":true,"info":{"id":1525,"presentation":"Targets and goals - The EAS way","session":"NLA\/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines","presenter":"Chris Packard, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5270.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/Chris Packard - EAS20 - Targets and goals the EAS way - 1525.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/2\/Chris Packard - EAS20 - Targets and goals the EAS way - 1525.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/55B039C5.jpg","data":[],"tracks":[]}]},{"name":"Targets and goals - The NLA way","mode":"playlist","public":true,"info":{"id":1526,"presentation":"Targets and goals - The NLA way","session":"NLA\/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines","presenter":"Carl E. Orringer, United States of America","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5397.jpg"},"playlist":[{"name":"Targets and goals - The NLA way","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/EAS20-1526.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/2\/EAS20-1526.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/C410C069.jpg","data":[],"tracks":[]}]},{"name":"Therapeutic Approaches - The EAS way","mode":"playlist","public":true,"info":{"id":1528,"presentation":"Therapeutic Approaches - The EAS way","session":"NLA\/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/Alberico L. Catapano - EAS20 - 1528 - Therapeutic Approaches - The EAS way.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/2\/Alberico L. Catapano - EAS20 - 1528 - Therapeutic Approaches - The EAS way.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/757174.jpg","data":[],"tracks":[]}]},{"name":"Therapeutic Approaches - The NLA way","mode":"playlist","public":true,"info":{"id":1529,"presentation":"Therapeutic Approaches - The NLA way","session":"NLA\/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines","presenter":"Christie Ballantyne, United States of America","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/Christie Ballantyne - EAS20 - 1529 - Therapeutic Approaches - The NLA Way.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/2\/Christie Ballantyne - EAS20 - 1529 - Therapeutic Approaches - The NLA Way.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/E593EACD.jpg","data":[],"tracks":[]}]}]

CME Session

The role of TG-rich lipoproteins in atherosclerosis

Session Type

CME Session

Chair(s)

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

15:30 - 17:00

Session Ticket

Session Evaluation

Please click here to evaluate your knowledge. Your input is appreciated!

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1579,"presentation":"Introduction","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Philippe Moulin, France","photo":""},"playlist":[{"name":"Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/Philippe Moulin - EAS20 - 1579 - Introduction.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/Philippe Moulin - EAS20 - 1579 - Introduction.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/28548063.jpg","data":[],"tracks":[]}]},{"name":"TG-rich lipoproteins as a risk factor","mode":"playlist","public":true,"info":{"id":1511,"presentation":"TG-rich lipoproteins as a risk factor","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Ruth Frikke-Schmidt, Denmark","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/619.jpg"},"playlist":[{"name":"TG-rich lipoproteins as a risk factor","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/EAS 1511 .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/EAS 1511 .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/F4BEE98F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/EAS 1511 .vtt"}]},{"name":"The value of omega 3: from biology to clinical practice","mode":"playlist","public":true,"info":{"id":1512,"presentation":"The value of omega 3: from biology to clinical practice","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Alberto Zambon, Italy","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/550.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/Alberto Zambon - EAS 2020 - 1512 - The value of omega 3 from biology to clinical practice.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/Alberto Zambon - EAS 2020 - 1512 - The value of omega 3 from biology to clinical practice.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/6614D78C.jpg","data":[],"tracks":[]}]},{"name":"Position of omega 3 in Guidelines (as second choice after statins)","mode":"playlist","public":true,"info":{"id":1513,"presentation":"Position of omega 3 in Guidelines (as second choice after statins)","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Christie Ballantyne, United States of America","photo":""},"playlist":[{"name":"Position of omega 3 in Guidelines (as second choice after statins","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/Christie M. Ballantyne MD EAS20 1513 Position of omega 3 in Guidelines (as second choice after statins.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/Christie M. Ballantyne MD EAS20 1513 Position of omega 3 in Guidelines (as second choice after statins.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/63228A2.jpg","data":[],"tracks":[]}]},{"name":"Case: Diabetic patient with MI - how to manage?","mode":"playlist","public":true,"info":{"id":1514,"presentation":"Case: Diabetic patient with MI - how to manage?","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Dirk M\u00fcller-Wieland, Germany","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/Dirk M\u00fcller-Wieland - EAS20 - 1514 - Case Diabetic patient with MI - how to manage.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/Dirk M\u00fcller-Wieland - EAS20 - 1514 - Case Diabetic patient with MI - how to manage.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/8AC98309.jpg","data":[],"tracks":[]}]},{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1536,"presentation":"Panel Discussion with Live Q&A","session":"The role of TG-rich lipoproteins in atherosclerosis","presenter":"Philippe Moulin, France, Jan Boren, Sweden, Ruth Frikke-Schmidt, Denmark, Alberto Zambon, Italy, Christie Ballantyne, United States of America, Dirk M\u00fcller-Wieland, Germany","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/619.jpg"},"playlist":[{"name":"The role of TG-rich lipoproteins in atherosclerosis","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/The role of TG-rich lipoproteins in atherosclerosis.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/107\/The role of TG-rich lipoproteins in atherosclerosis.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/107\/AA505DC4.jpg","data":[],"tracks":[]}]}]

CME Session

Novel approaches to lipid lowering management

Session Type

CME Session

Chair(s)

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

17:00 - 18:30

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1580,"presentation":"Introduction","session":"Novel approaches to lipid lowering management","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1580-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/5FF2F12B.jpg","data":[],"tracks":[]}]},{"name":"What is the landscape on lipid management today?","mode":"playlist","public":true,"info":{"id":1505,"presentation":"What is the landscape on lipid management today?","session":"Novel approaches to lipid lowering management","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"1505 - What is the landscape on lipid management today?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/105_1505_2.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/105_1505_2.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/593A446A.jpg","data":[],"tracks":[]}]},{"name":"When do we need add on therapies to statin?","mode":"playlist","public":true,"info":{"id":1506,"presentation":"When do we need add on therapies to statin?","session":"Novel approaches to lipid lowering management","presenter":"Ulrich Laufs, Germany","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Ulrich Laufs - EAS20-1506-When Do We Need Add on Therapies to Statin.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Ulrich Laufs - EAS20-1506-When Do We Need Add on Therapies to Statin.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/7EA9942E.jpg","data":[],"tracks":[]}]},{"name":"What do we know so far about bempedoic acid?","mode":"playlist","public":true,"info":{"id":1507,"presentation":"What do we know so far about bempedoic acid?","session":"Novel approaches to lipid lowering management","presenter":"Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Kausik Ray - EAS20- 1507- What do we know so far about bempedoic acid.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Kausik Ray - EAS20- 1507- What do we know so far about bempedoic acid.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/AED7C78A.jpg","data":[],"tracks":[]}]},{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1581,"presentation":"Panel Discussion with Live Q&A","session":"Novel approaches to lipid lowering management","presenter":"Marja-Riitta Taskinen, Finland, Alberico Luigi Catapano, Italy, Lale Tokg\u00f6zo\u011flu, Turkey, Ulrich Laufs, Germany, Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5369.jpg"},"playlist":[{"name":"Novel approaches to lipid lowering management","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/D568E245.jpg","data":[],"tracks":[]}]}]

Plenary

Opening Ceremony including Anitschkow Lecture

Session Type

Plenary

Room

Hall 1

Date

04.10.2020, Sunday

Session Time

19:00 - 20:30

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Welcome by EAS President","mode":"playlist","public":true,"info":{"id":1568,"presentation":"Welcome by EAS President","session":"Opening Ceremony including Anitschkow Lecture","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"Welcome by President","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/1 - Lale - 1568 - Geneva Movie Introduction.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/4\/1 - Lale - 1568 - Geneva Movie Introduction.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/CFBF13D3.jpg","data":[],"tracks":[]}]},{"name":"Welcome by Congress Chair","mode":"playlist","public":true,"info":{"id":1781,"presentation":"Welcome by Congress Chair","session":"Opening Ceremony including Anitschkow Lecture","presenter":"Fran\u00e7ois Mach, Switzerland","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"Intro","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/2.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/4\/2.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/3C6B714.jpg","data":[],"tracks":[]}]},{"name":"Welcome by IAS President","mode":"playlist","public":true,"info":{"id":1569,"presentation":"Welcome by IAS President","session":"Opening Ceremony including Anitschkow Lecture","presenter":"Raul D. Santos, Brazil","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/3700.jpg"},"playlist":[{"name":"1569-Welcome by IAS President","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/1569 - Welcome by IAS President.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/4\/1569 - Welcome by IAS President.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/ACF14D63.jpg","data":[],"tracks":[]}]},{"name":"Young Investigator and Anitschkow awards","mode":"playlist","public":true,"info":{"id":1779,"presentation":"Young Investigator and Anitschkow awards","session":"Opening Ceremony including Anitschkow Lecture","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"YIA Intro","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/5 - Lale -1779 - YIA Introduction.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/4\/5 - Lale -1779 - YIA Introduction.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/AFA9D3DC.jpg","data":[],"tracks":[]}]},{"name":"Anitschkow Lecture - The Oxidation Hypothesis of Atherosclerosis Revisited: A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation","mode":"playlist","public":true,"info":{"id":1533,"presentation":"Anitschkow Lecture - The Oxidation Hypothesis of Atherosclerosis Revisited: A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation","session":"Opening Ceremony including Anitschkow Lecture","presenter":"Joseph L. Witztum, United States of America","photo":""},"playlist":[{"name":"Anitschkow Lecture - The Oxidation Hypothesis of Atherosclerosis Revisited: A Pivotal Role of OxPL i","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/EAS201533.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/4\/EAS201533.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/4\/1D41ABF.jpg","data":[],"tracks":[]}]}]

Introduction

Introduction to the scientific programme

Session Type

Introduction

Room

Hall 1

Date

05.10.2020, Monday

Session Time

08:00 - 08:05

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

Plenary

NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES

Session Type

Plenary

Chair(s)

François Mach, Switzerland

Room

Hall 1

Date

05.10.2020, Monday

Session Time

08:30 - 09:53

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1541,"presentation":"Introduction","session":"NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES","presenter":"Fran\u00e7ois Mach, Switzerland","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/Francois Mach EAS20 1541 Introduction.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/7\/Francois Mach EAS20 1541 Introduction.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/777BA4ED.jpg","data":[],"tracks":[]}]},{"name":"Global perspectives of cardiovascular disease, and impact of risk factors","mode":"playlist","public":true,"info":{"id":1419,"presentation":"Global perspectives of cardiovascular disease, and impact of risk factors","session":"NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES","presenter":"Gregory Roth, United States of America","photo":""},"playlist":[{"name":"Global perspectives of cardiovascular disease, and impact of risk factors.","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/Greg Roth EAS20 1419 Global perspectives of cardiovascular disease, and impact of risk factors.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/7\/Greg Roth EAS20 1419 Global perspectives of cardiovascular disease, and impact of risk factors.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/EB288B7A.jpg","data":[],"tracks":[]}]},{"name":"Can polygenic scores reach clinical practice?","mode":"playlist","public":true,"info":{"id":1420,"presentation":"Can polygenic scores reach clinical practice?","session":"NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES","presenter":"Anne Tybj\u00e6rg-Hansen, Denmark","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/620.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/Anne Tybjaerg-Hansen - EAS20 - ID 1420 - Can polygenic scores reach clinical practice.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/7\/Anne Tybjaerg-Hansen - EAS20 - ID 1420 - Can polygenic scores reach clinical practice.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/A461EC83.jpg","data":[],"tracks":[]}]},{"name":"What is the environment doing to cardiovascular health?","mode":"playlist","public":true,"info":{"id":1421,"presentation":"What is the environment doing to cardiovascular health?","session":"NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES","presenter":"Nicole Probst-Hensch, Switzerland","photo":""},"playlist":[{"name":"Nicole Probst-Hensch - 1421 - What is the environment doing to cardiovascular health?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/Nicole Probst-Hensch - 1421 - What is the environment doing to cardiovascular health.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/7\/Nicole Probst-Hensch - 1421 - What is the environment doing to cardiovascular health.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/86989C0F.jpg","data":[],"tracks":[]}]},{"name":"Age, the unpreventable risk factor - targeting senescence","mode":"playlist","public":true,"info":{"id":1422,"presentation":"Age, the unpreventable risk factor - targeting senescence","session":"NATURE AND NURTURE - IMPACT OF TRADITIONAL RISK FACTORS, ENVIRONMENT AND GENES","presenter":"Jan Van Deursen, United States of America","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/Jan van Deursen - EAS20-1422- Age, the Unpreventable Risk Factor - Targeting Senescence v2.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/7\/Jan van Deursen - EAS20-1422- Age, the Unpreventable Risk Factor - Targeting Senescence v2.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/7\/85BC7E6A.jpg","data":[],"tracks":[]}]}]

Joint symposium

ESC-EAS joint symposium - A Deep Dive into ESC/EAS Dyslipidemia Guidelines

Session Type

Joint symposium

Chair(s)

Lale Tokgözoğlu, Turkey

Room

Hall 1

Date

05.10.2020, Monday

Session Time

10:00 - 11:10

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1542,"presentation":"Introduction","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/Lale Intro.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/Lale Intro.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/68B3C613.jpg","data":[],"tracks":[]}]},{"name":"How to approach a patient with dyslipidemia without apparent CAD","mode":"playlist","public":true,"info":{"id":1772,"presentation":"How to approach a patient with dyslipidemia without apparent CAD","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Baris Gencer, Switzerland","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/Baris Gencer - EAS20 - 1772 - How to approach a patient with dyslipidaemia without apparent CAD.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/Baris Gencer - EAS20 - 1772 - How to approach a patient with dyslipidaemia without apparent CAD.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/5C593835.jpg","data":[],"tracks":[]}]},{"name":"How to approach a patient with dyslipidemia without apparent CAD. What the guideline says.","mode":"playlist","public":true,"info":{"id":1423,"presentation":"How to approach a patient with dyslipidemia without apparent CAD. What the guideline says.","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Victoria Delgado, Netherlands","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5317.jpg"},"playlist":[{"name":"How to approach a patient with dyslipidemia without apparent CAD (case by young fellow) What the gui","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/1423.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/1423.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/F95B53DA.jpg","data":[],"tracks":[]}]},{"name":"What is the critical evidence behind the guideline:","mode":"playlist","public":true,"info":{"id":1424,"presentation":"What is the critical evidence behind the guideline:","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"What is the critical evidence","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/20.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/20.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/685A78AF.jpg","data":[],"tracks":[]}]},{"name":"How to approach a patient with dyslipidemia with CAD","mode":"playlist","public":true,"info":{"id":1773,"presentation":"How to approach a patient with dyslipidemia with CAD","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Anna Lebedeva, Russian Federation","photo":""},"playlist":[{"name":"How to approach a patient with dyslipidemia with CAD","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/1773 attempt 1.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/1773 attempt 1.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/F7187F4.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/1773 attempt 1.vtt"}]},{"name":"How to approach a patient with dyslipidemia with CAD (case by young fellow) What the guideline says","mode":"playlist","public":true,"info":{"id":1425,"presentation":"How to approach a patient with dyslipidemia with CAD (case by young fellow) What the guideline says","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Fran\u00e7ois Mach, Switzerland","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"Mach- EAS20 - 1425 -How to approach a patient with dyslipidemia with CAD (case by young fellow) Wha","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/1425.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/1425.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/761BA67A.jpg","data":[],"tracks":[]}]},{"name":"What is the critical evidence behind the guideline:","mode":"playlist","public":true,"info":{"id":1426,"presentation":"What is the critical evidence behind the guideline:","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1426-What is the critical evidence behind the guideline:","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/EAS201426.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/EAS201426.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/E1EAE43A.jpg","data":[],"tracks":[]}]}]

Track 3 - Pathogenesis of Atherosclerosis

Non coding RNA and epigenetic regulators

Session Type

Track 3 - Pathogenesis of Atherosclerosis

Chair(s)

Christina Christoffersen, Denmark

Room

Hall 2

Date

05.10.2020, Monday

Session Time

10:00 - 11:13

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1543,"presentation":"Introduction","session":"Non coding RNA and epigenetic regulators","presenter":"Christina Christoffersen, Denmark","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5231.jpg"},"playlist":[{"name":"Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/Christina Christoffersen EAS 20 1543 Introduction01.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/Christina Christoffersen EAS 20 1543 Introduction01.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/44DDAC90.jpg","data":[],"tracks":[]}]},{"name":"High-resolution regulatory maps connect vascular risk variants to disease-related pathways","mode":"playlist","public":true,"info":{"id":1428,"presentation":"High-resolution regulatory maps connect vascular risk variants to disease-related pathways","session":"Non coding RNA and epigenetic regulators","presenter":"Pelin Sahlen, Sweden","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/3262.jpg"},"playlist":[{"name":"High-resolution regulatory maps connect vascular risk variants to disease-related pathways","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/Pelin Sahl\u00e9n - EAS20 - 1428 - High-resolution regulatory maps connect vascular risk variants to disease-related pathways.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/Pelin Sahl\u00e9n - EAS20 - 1428 - High-resolution regulatory maps connect vascular risk variants to disease-related pathways.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/BE84C8E0.jpg","data":[],"tracks":[]}]},{"name":"Chromatin modifications by the methyltransferase SETD7 modulate angiogenic response in diabetes: insights for epigenetic-based therapies","mode":"playlist","public":true,"info":{"id":1348,"presentation":"Chromatin modifications by the methyltransferase SETD7 modulate angiogenic response in diabetes: insights for epigenetic-based therapies","session":"Non coding RNA and epigenetic regulators","presenter":"Shafeeq A. Mohammed, Switzerland","photo":""},"playlist":[{"name":"Chromatin modifications by the methyltransferase SETD7 modulate angiogenic response in diabetes: ins","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/P1348 - Final.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/P1348 - Final.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/25EFAD18.jpg","data":[],"tracks":[]}]},{"name":"Deletion of Hepatic NCOR1 Confers Atheroprotection","mode":"playlist","public":true,"info":{"id":794,"presentation":"Deletion of Hepatic NCOR1 Confers Atheroprotection","session":"Non coding RNA and epigenetic regulators","presenter":"Sokrates Stein, Switzerland","photo":""},"playlist":[{"name":"Deletion of Hepatic NCOR1 Confers Atheroprotection","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/EAS20 794.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/EAS20 794.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/C9EFB759.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/EAS20 794.vtt"}]},{"name":"Switching Macrophage Gene Expression From Inflammation-Resolution to Hemorrhage-Resolution by Redirection of Activating Transcription Factor 1 (ATF1) Binding by SMARCA4, BACH1 and Histone H3K9 Acetylation","mode":"playlist","public":true,"info":{"id":1024,"presentation":"Switching Macrophage Gene Expression From Inflammation-Resolution to Hemorrhage-Resolution by Redirection of Activating Transcription Factor 1 (ATF1) Binding by SMARCA4, BACH1 and Histone H3K9 Acetylation","session":"Non coding RNA and epigenetic regulators","presenter":"Joseph J. Boyle, United Kingdom","photo":""},"playlist":[{"name":"Switching Macrophage Gene Expression From Inflammation-Resolution to Hemorrhage-Resolution by Redire","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/Joseph J Boyle - EAS20 1024 Switching Macrophage Gene Expression From Inflammation-Resolution to Hemorrhage-Rsolution by Redirection of Activating Transcription Factor 1 (ATF1) Bindin_edit.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/Joseph J Boyle - EAS20 1024 Switching Macrophage Gene Expression From Inflammation-Resolution to Hemorrhage-Rsolution by Redirection of Activating Transcription Factor 1 (ATF1) Bindin_edit.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/279C4F9C.jpg","data":[],"tracks":[]}]},{"name":"The multifactorial nature of microRNAs in vascular remodelling","mode":"playlist","public":true,"info":{"id":1427,"presentation":"The multifactorial nature of microRNAs in vascular remodelling","session":"Non coding RNA and epigenetic regulators","presenter":"Yael Nossent, Austria","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5336.jpg"},"playlist":[{"name":"The multifactorial nature of microRNAs in vascular remodelling","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/1427 .mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/1427 .mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/792C15E7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/1427 .vtt"}]},{"name":"M2 macrophage exosomes regulate hematopoiesis & resolve inflammation in atherosclerosis via microRNA cargo","mode":"playlist","public":true,"info":{"id":1288,"presentation":"M2 macrophage exosomes regulate hematopoiesis & resolve inflammation in atherosclerosis via microRNA cargo","session":"Non coding RNA and epigenetic regulators","presenter":"Laura Bouchareychas, United States of America","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/Laura Bouchareychas - EAS20- 1288 - M2 Macrophage Exosomes Regulate Hematopoiesis & Resolve Inflammation in Atherosclerosis via Microrna Cargo.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/Laura Bouchareychas - EAS20- 1288 - M2 Macrophage Exosomes Regulate Hematopoiesis & Resolve Inflammation in Atherosclerosis via Microrna Cargo.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/39D77837.jpg","data":[],"tracks":[]}]},{"name":"Endothelial miRNAs reduce leukocyte adhesion by modulating inflammatory signal transduction pathways","mode":"playlist","public":true,"info":{"id":1158,"presentation":"Endothelial miRNAs reduce leukocyte adhesion by modulating inflammatory signal transduction pathways","session":"Non coding RNA and epigenetic regulators","presenter":"Hector Giral, Germany","photo":""},"playlist":[{"name":"1158-Endothelial miRNAs reduce leukocyte adhesion by modulating inflammatory signal transduction pat","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/Hector Giral Arnal - EAS20 - 1158- Endothelial Mirnas Reduce Leukocyte Adhesion.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/9\/Hector Giral Arnal - EAS20 - 1158- Endothelial Mirnas Reduce Leukocyte Adhesion.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/9\/693A0B7E.jpg","data":[],"tracks":[]}]}]

Track 2 - Metabolism of Lipids and Lipoproteins

Lipoprotein receptors and lipid transport

Session Type

Track 2 - Metabolism of Lipids and Lipoproteins

Chair(s)

Noam Zelcer, Netherlands

Room

Hall 3

Date

05.10.2020, Monday

Session Time

10:00 - 11:13

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1544,"presentation":"Introduction","session":"Lipoprotein receptors and lipid transport","presenter":"Noam Zelcer, Netherlands","photo":""},"playlist":[{"name":"Noam Zelcer - EAS20 - 1544 -Introduction by Chair","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/1544.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/1544.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/EFFBC422.jpg","data":[],"tracks":[]}]},{"name":"Role of the retromer COMMD\/WASH complex","mode":"playlist","public":true,"info":{"id":1429,"presentation":"Role of the retromer COMMD\/WASH complex","session":"Lipoprotein receptors and lipid transport","presenter":"Bart Van de Sluis, Netherlands","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5290.jpg"},"playlist":[{"name":"Role of the retromer COMMD\/WASH complex","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/P1429.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/P1429.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/E4B8DF7B.jpg","data":[],"tracks":[]}]},{"name":"LRP1 derived peptides as a therapeutic strategy in atherosclerosis. Biochemical, in vitro and in vivo studies","mode":"playlist","public":true,"info":{"id":1373,"presentation":"LRP1 derived peptides as a therapeutic strategy in atherosclerosis. Biochemical, in vitro and in vivo studies","session":"Lipoprotein receptors and lipid transport","presenter":"Aleyda Benitez Amaro, Spain","photo":""},"playlist":[{"name":"LRP1 derived peptides as a therapeutic strategy in atherosclerosis. Biochemical, in vitro and in viv","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/Aleyda Benitez Amaro EAS20 1373 LRP1 derived peptides as a therapeutic strategy in atherosclerosis Biochemical in vitro and in vivo studies.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/Aleyda Benitez Amaro EAS20 1373 LRP1 derived peptides as a therapeutic strategy in atherosclerosis Biochemical in vitro and in vivo studies.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/ABFE7643.jpg","data":[],"tracks":[]}]},{"name":"Deletion of the apoCIII gene in knockout rabbits attenuates cholesterol diet-induced hyperlipidemia and protects against atherosclerosis","mode":"playlist","public":true,"info":{"id":846,"presentation":"Deletion of the apoCIII gene in knockout rabbits attenuates cholesterol diet-induced hyperlipidemia and protects against atherosclerosis","session":"Lipoprotein receptors and lipid transport","presenter":"Haizhao Yan, Japan","photo":""},"playlist":[{"name":"Deletion of the apoCIII gene in knockout rabbits attenuates cholesterol diet-induced hyperlipidemia","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/Haizhao Yan - EAS20 - 846 - Deletion of the apoCIII gene in knockout rabbits attenuates cholesterol diet-induced hyperlipidemia and protects against atherosclerosis.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/Haizhao Yan - EAS20 - 846 - Deletion of the apoCIII gene in knockout rabbits attenuates cholesterol diet-induced hyperlipidemia and protects against atherosclerosis.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/6A443D00.jpg","data":[],"tracks":[]}]},{"name":"Characteristics of monogenic versus polygenic familial hypobetalipoproteinemia","mode":"playlist","public":true,"info":{"id":1368,"presentation":"Characteristics of monogenic versus polygenic familial hypobetalipoproteinemia","session":"Lipoprotein receptors and lipid transport","presenter":"Antoine Rimbert, France","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/Antoine Rimbert - EAS20 - ID 1368 - Characteristics of monogenic versus polygenic familial hypobetalipoproteinemia.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/Antoine Rimbert - EAS20 - ID 1368 - Characteristics of monogenic versus polygenic familial hypobetalipoproteinemia.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/4DF3253F.jpg","data":[],"tracks":[]}]},{"name":"Lipoprotein transport in the brain","mode":"playlist","public":true,"info":{"id":1430,"presentation":"Lipoprotein transport in the brain","session":"Lipoprotein receptors and lipid transport","presenter":"Francesca Zimetti, Italy","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/3165.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/Francesca Zimetti - EAS20 - 1430 - Lipoprotein transport in the brain.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/10\/Francesca Zimetti - EAS20 - 1430 - Lipoprotein transport in the brain.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/10\/586B473.jpg","data":[],"tracks":[]}]}]

Track 4 - Prevention and Treatment of CVD

Who are the highest risk patients and how do we manage them?

Session Type

Track 4 - Prevention and Treatment of CVD

Room

Hall 4

Date

05.10.2020, Monday

Session Time

10:00 - 11:13

Session Ticket

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Acute coronary syndrome patients","mode":"playlist","public":true,"info":{"id":1432,"presentation":"Acute coronary syndrome patients","session":"Who are the highest risk patients and how do we manage them?","presenter":"Jose Luis Zamorano, Spain","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5362.jpg"},"playlist":[{"name":"Acute coronary syndrome patients","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/P1432 - new.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/P1432 - new.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/9DF773C8.jpg","data":[],"tracks":[]}]},{"name":"Chronic kidney disease patients","mode":"playlist","public":true,"info":{"id":1431,"presentation":"Chronic kidney disease patients","session":"Who are the highest risk patients and how do we manage them?","presenter":"Colin Baigent, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5305.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/EAS20 - Colin Baigent - ID1431 - Chronic kidney disease patients2.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/EAS20 - Colin Baigent - ID1431 - Chronic kidney disease patients2.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/736476FC.jpg","data":[],"tracks":[]}]},{"name":"Association between Apolipoprotein B and cardiovascular risk: a meta-analysis of randomized controlled trials","mode":"playlist","public":true,"info":{"id":628,"presentation":"Association between Apolipoprotein B and cardiovascular risk: a meta-analysis of randomized controlled trials","session":"Who are the highest risk patients and how do we manage them?","presenter":"Federica Galimberti, United Kingdom","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/Federica Galimberti - EAS20 - 628 - Association between Apolipoprotein B and cardiovascular risk - a meta-analysis of randomized controlled trials.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/Federica Galimberti - EAS20 - 628 - Association between Apolipoprotein B and cardiovascular risk - a meta-analysis of randomized controlled trials.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/1C481894.jpg","data":[],"tracks":[]}]},{"name":"Specification of ACMG\/AMP guidelines for standardized variant interpretation in familial hypercholesterolemia: On behalf of the ClinGen FH Variant Curation Expert Panel","mode":"playlist","public":true,"info":{"id":340,"presentation":"Specification of ACMG\/AMP guidelines for standardized variant interpretation in familial hypercholesterolemia: On behalf of the ClinGen FH Variant Curation Expert Panel","session":"Who are the highest risk patients and how do we manage them?","presenter":"Joana R. Chora, Portugal","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/Joana Chora - EAS20- 340- Specification of AcmgAmp Guidelines for Standardized Variant Interpretation in Familial Hypercholesterolemia On Behalf of the Clingen Fh Variant.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/Joana Chora - EAS20- 340- Specification of AcmgAmp Guidelines for Standardized Variant Interpretation in Familial Hypercholesterolemia On Behalf of the Clingen Fh Variant.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/59560DD3.jpg","data":[],"tracks":[]}]},{"name":"Hypercholesterolemia disrupts the metabolic regulation of hematopoietic stem cell behavior, favoring the production of pro-inflammatory monocytes in patients with familial hypercholesterolemia","mode":"playlist","public":true,"info":{"id":1036,"presentation":"Hypercholesterolemia disrupts the metabolic regulation of hematopoietic stem cell behavior, favoring the production of pro-inflammatory monocytes in patients with familial hypercholesterolemia","session":"Who are the highest risk patients and how do we manage them?","presenter":"Lotte C. Stiekema, Netherlands","photo":""},"playlist":[{"name":"Lotte Stiekema - EAS20 - 1036 - Hypercholesterolemia disrupts the metabolic regulation of hematopoie","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/Lotte Stiekema - EAS20 - 1036 - Hypercholesterolemia disrupts the metabolic regulation of hematopoietic stem cell behavior.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/Lotte Stiekema - EAS20 - 1036 - Hypercholesterolemia disrupts the metabolic regulation of hematopoietic stem cell behavior.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/BED35CD7.jpg","data":[],"tracks":[]}]},{"name":"Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention","mode":"playlist","public":true,"info":{"id":1291,"presentation":"Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention","session":"Who are the highest risk patients and how do we manage them?","presenter":"Blake J. Cochran, Australia","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/EAS20-ID1291-Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/11\/EAS20-ID1291-Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/11\/F24D025F.jpg","data":[],"tracks":[]}]}]

51 Sessions

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast

Session Webcast